(Q37639898)

21 August 2017

1 reference

title

More is less -- combining targeted therapies in metastatic colorectal cancer (English)

1 reference

21 August 2017

1 reference

Cornelis J A Punt

1

1 reference

21 August 2017

Jolien Tol

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Nature Reviews Clinical Oncology

21 August 2017

published in

1 reference

21 August 2017

volume

6

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

731-733

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Moyamoya disease and moyamoya syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

EGFR, HER-2 and COX-2 levels in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.168

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19942926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Early biotransformations of oxaliplatin after its intravenous administration to cancer patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19942926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

BRAFMutation in Metastatic Colorectal Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19942926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2009.168

1 reference

21 August 2017

1 reference